Atlas Trials

HAIC Combined With Camrelizumab and TKI for Unresectable Hepatocellular Carcinoma After TACE Failure

Clinical trial NCT05135364 · UNKNOWN

Trial details

NCT number
NCT05135364
Sponsor
Yue Han
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
Unresectable Hepatocellular Carcinoma
Start date
2021-11-05
Primary completion
2022-10-05
Enrollment
48

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.